Bristol Myers' admilparant trial reports patient death, raises liver safety questions
Bristol Myers Squibb disclosed a patient death and liver-related safety events in testing of admilparant for lung disease, leading to trial protocol revisions and raising concerns about the new class of fibrosis drugs ahead of an upcoming readout.
